CureVac AG

CureVac AG : German mRNA company with a diversified pipeline; Ph 2a trial ongoing with COVID-19 vaccine candidate, CVnCoV. Global Ph 2/3 trial enrolling approx. 36,500 participants with results expected 1Q21. Three other programs in Ph 1: CV8102 (cutaneous melanoma, adenoidcystic carcinoma, squamous cell cancer of skin, head & neck), CV9202 (NSCLC) and CV7202 (Rabies). mRNA-based antibody delivery deal with Genmab (Dec'19). Other strategic partnerships include GSK and CRISPR Tx.

Sector/Industry:

Healthcare/Biotechnology

Characteristics:

Based in...

Europe

Clinical Stage

Phase III

Disease Space

Anti-infectives, Antivirals, Autoimmune, COVID-19, Infectious Disease, Oncology, Ophthalmology

Finance

Pre-Revenues

Industry

Biotechnology

Investement Strategy

Under the Radar

Listing

Public, USA

Market Cap

1B +

Therapeutic Modalities

Platform Technology, Vaccine

Website:

http://www.curevac.com/

Profiles:

Address:

Paul-Ehrlich-Straße 15
Tübingen, Baden-Wurttemberg 72076
Germany

Presentation:

Company Presentation

More info:

Send Message to Request Information

My account:

Company Participants at 2020 Wall Street "On Tap"

Franz-Werner Haas

CureVac AG, Chief Executive Officer, Chief Operating Officer

Franz-Werner Haas joined CureVac in June 2012. Before joining CureVac, he was Vice President Operations and Chief Compliance Officer of SYGNIS Pharma AG, where he was responsible for the execution of M&A and capital market transactions. Franz-Werner started his professional career as an assistant to the management of a privately-held holding company before assuming several management positions in the Life Science Industry, including Vice President and General Counsel of LION bioscience and General Counsel of Sirona Dental Systems. He studied law at the University of Saarbruecken, K.U. Leuven and the University of Edinburgh (LL.M.).

Top 10 Holders of CureVac N.V.

Institution	OS (%)	Position	Mkt Val ($MM)	Source	Filing Date
Baillie Gifford & Co.	2.19	3,896,475	391.01	13F	9/30/20
T. Rowe Price Associates, Inc. (Investment Management)	0.68	1,202,421	120.66	13F	9/30/20
DekaBank Deutsche Girozentrale	0.24	435,500	43.70	13F	9/30/20
Samsara Biocapital LLC	0.21	370,385	37.17	13F	9/30/20
Millennium Management LLC	0.17	304,637	30.57	13F	9/30/20
Novo Holding A/S	0.11	201,642	20.23	13F	9/30/20
Hillhouse Capital Advisors Ltd. (Cayman Islands)	0.10	186,183	18.68	13F	9/30/20
Vivo Capital LLC	0.10	169,825	17.04	13F	9/30/20
Geode Capital Management LLC	0.07	130,878	13.13	13F	9/30/20
Susquehanna Securities LLC	0.07	125,536	12.60	13F	9/30/20

Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...

Market Data copyright © 2021 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.